학술논문
Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice
Document Type
Article
Author
Source
In Joint Bone Spine July 2014 81(4):352-359
Subject
Language
ISSN
1297-319X